BPCIA Patent Dance

The BPCIA patent dance under 42 U.S.C. § 262(l) is a detailed procedural sequence designed to identify patent disputes before biosimilar launch: STEP 1 — aBLA DISCLOSURE (§ 262(l)(2)(A)): within 20 days of FDA acceptance of the biosimilar's § 351(k) application, the biosimilar applicant must provide the reference product sponsor (RPS) with a copy of the aBLA application and any information describing the process or processes used to manufacture the biological product; this is the foundational step that triggers the rest of the dance; STEP 2 — RPS PATENT LIST (§ 262(l)(3)(A)): within 60 days of receiving the biosimilar application, the RPS provides a list of patents it believes could be enforced against the biosimilar applicant and its licensed patents it reasonably believes could be asserted; STEP 3 — BIOSIMILAR RESPONSE (§ 262(l)(3)(B)): within 60 days of receiving the RPS list, the biosimilar applicant provides: (i) a list of patents the biosimilar applicant believes should be included in a patent infringement action; (ii) for each patent on the RPS list that the biosimilar applicant did NOT include, a detailed statement of invalidity, unenforceability, or non-infringement; STEP 4 — RPS RESPONSE (§ 262(l)(3)(C)): within 60 days of receiving the biosimilar applicant's lists, the RPS provides a response to the biosimilar applicant's invalidity/non-infringement statements, including a detailed statement for each patent; STEP 5 — NEGOTIATION (§ 262(l)(4)): within 15 days of the RPS providing its step 4 response, the parties engage in good-faith negotiations to identify patents for immediate litigation (the 'list 1 patents' — patents to be litigated immediately); STEP 6 — LITIGATION (§ 262(l)(6)): if the parties AGREE on list 1 patents: both parties shall file a patent infringement suit within 30 days; if the parties DO NOT AGREE: the RPS selects a specific number of patents (not to exceed the number agreed by the parties or, if no number agreed, then whichever is smaller: one patent or the number of patents in the RPS list) and files suit within 30 days; STEPS 7-11 — LITIGATION PROCEEDINGS: the litigation over the list 1 patents proceeds through the courts; STEP 11/12 — LIST 2 PATENTS (§ 262(l)(8)): any patents not included in the list 1 litigation can only be asserted after the biosimilar applicant provides 180-day pre-commercial marketing notice; these 'list 2 patents' are the subject of a later phase of litigation after the 180-day notice is given; THE 180-DAY NOTICE (§ 262(l)(8)(A)): after FDA approval of the biosimilar, the biosimilar applicant must give the RPS at least 180-day notice before commercial marketing begins; the RPS can then seek a preliminary injunction on list 2 patents during this 180-day window.

The Supreme Court resolved the mandatory vs. optional question definitively in Amgen Inc. v. Sandoz Inc. (S.Ct. 2017): THE PRE-SANDOZ SPLIT: The Federal Circuit had split on whether the patent dance was mandatory or optional: Sandoz Inc. v. Amgen Inc. (Fed. Cir. 2015) initially held it was mandatory in some respects; the circuit eventually certified the question to the Supreme Court; THE SUPREME COURT DECISION: the Supreme Court unanimously held: (1) The patent dance information exchange (Step 1 — providing the aBLA to the RPS) is NOT mandatory — it is optional; (2) A biosimilar applicant may choose not to provide the aBLA application to the RPS; (3) The consequences of not providing the application: the RPS may immediately bring a declaratory judgment action for patent infringement under § 271(e)(2)(C); all patents not otherwise litigated become 'list 2 patents' subject only to post-180-day-notice litigation; (4) The 180-day pre-commercial marketing notice IS mandatory; even if the biosimilar applicant opts out of the patent dance, it must still give the RPS at least 180 days notice before commercial marketing; AFTER THE DECISION: the Supreme Court also decided that the only remedy for failing to provide the aBLA in step 1 is the patent infringement suit under § 271(e)(2) — there is no separate injunctive remedy specifically for the failure to provide the aBLA; WHAT THIS MEANS STRATEGICALLY: BIOSIMILAR APPLICANT choosing to OPT OUT: denies the RPS access to manufacturing details that could support claim construction and infringement mapping; accepts that the RPS can sue immediately without waiting for the dance to complete; is still bound by the 180-day notice requirement for commercial marketing; BIOSIMILAR APPLICANT choosing to PARTICIPATE: gets clarity on which patents the RPS considers relevant; can force the RPS to commit to its positions early; creates record of the RPS's positions for claim construction and invalidity arguments; PRACTICAL IMPACT: many biosimilar applicants participate in the dance because knowing which patents the RPS considers infringed is valuable for planning; some applicants with strong invalidity positions (particularly weak second-generation patents they believe invalid) prefer to opt out to avoid disclosing manufacturing details.

The BPCIA patent dance and the Hatch-Waxman Orange Book system share the same conceptual goal — resolving patent disputes before generic/biosimilar market entry — but differ fundamentally in structure: HATCH-WAXMAN ORANGE BOOK SYSTEM: MECHANISM: brand drug company lists patents in the FDA Orange Book within 30 days of patent issuance; ANDA filer selects one of four certifications (Para I, II, III, or IV) for each listed patent; Para IV = patent invalid or not infringed; TRIGGER: Para IV certification automatically sends notice to the brand company and patent holder; AUTOMATIC STAY: filing a lawsuit within 45 days of receiving Para IV notice triggers an AUTOMATIC 30-month stay of FDA approval; no court order required; no four-factor analysis; the stay runs automatically from the date of the original NDA approval or the Para IV notification date (whichever is later); SCOPE: only patents listed in the Orange Book; non-Orange Book patents cannot get the 30-month automatic stay (though they can be enforced separately); FIRST-FILER 180-DAY EXCLUSIVITY: first generic to file Para IV gets 180-day marketing exclusivity against subsequent generics; BPCIA PATENT DANCE: MECHANISM: much more complex 12-step information exchange process; no equivalent 'list' that is pre-published (the patent list is exchanged privately between parties); no Para IV equivalent — positions are exchanged in detailed written statements; TRIGGER: litigation is actively triggered by completing the dance and identifying list 1 patents; NO AUTOMATIC STAY: there is no automatic 30-month stay in BPCIA; if the RPS wants to block biosimilar launch, it must apply for a preliminary injunction; court applies four-factor eBay standard: likelihood of success, irreparable harm, balance of hardships, public interest; courts have been reluctant to grant preliminary injunctions in biosimilar cases; SCOPE: any patent the RPS lists within 60 days of receiving the aBLA — not limited to FDA-listed patents; 180-DAY NOTICE: mandatory notice before commercial marketing, unlike Hatch-Waxman where the 30-month stay provides similar protection; BOTTOM LINE DIFFERENCE: Hatch-Waxman creates far stronger and more automatic patent protection for brand companies (automatic 30-month stay); BPCIA requires brand companies to litigate and win preliminary injunctions to delay biosimilar market entry, which is much harder.

The dance opt-in/opt-out decision is one of the most important early strategic choices in biosimilar litigation: REASONS TO PARTICIPATE IN THE DANCE: (1) EARLY PATENT IDENTIFICATION: participation forces the RPS to identify which patents it believes are infringed within 60 days; the biosimilar applicant learns the full scope of the patent risk early; (2) LOCKING DOWN RPS POSITIONS: the detailed position statements in steps 3 and 4 create a record of the RPS positions; these statements can be used in claim construction and invalidity arguments; the RPS may be limited to the infringement theories it articulated in step 4; (3) NARROWING THE CASE: the dance can narrow the patents in dispute to a manageable list 1; the biosimilar applicant may argue that certain patents should not be on the list 1; (4) SIGNALING STRENGTH: participation with strong invalidity arguments signals confidence in the biosimilar applicant's IP position; REASONS TO OPT OUT OF THE DANCE: (1) PROTECTING MANUFACTURING INFORMATION: the step 1 disclosure provides the RPS with detailed manufacturing information that could be used to map claim elements to the biosimilar process; opting out denies this information to the RPS; particularly important when: the biosimilar uses a novel proprietary manufacturing process; manufacturing details are highly competitively sensitive; (2) FORCING EARLY LITIGATION ONLY ON PATENTS THE RPS CAN SEE: if the biosimilar applicant opts out, the RPS must sue based on what it knows publicly without the detailed manufacturing disclosure; this may expose the RPS to early invalidity arguments before it has mapped the biosimilar manufacturing steps; (3) STRATEGIC TIMING: opting out can sometimes delay the patent resolution timeline; (4) SIMPLICITY: smaller biosimilar companies may prefer the simpler litigation path rather than the complex multi-stage dance; POST-DECISION CONSIDERATIONS: after Amgen v. Sandoz, both strategies are legally valid; most sophisticated biosimilar companies conduct a careful patent-by-patent analysis before deciding; the choice often depends on whether the RPS's likely patents are stronger (favoring opt-out to protect manufacturing details) or weaker (favoring participation to lock down early invalidity positions).